Rare disease

Factor IX deficiency

13 clinical trials

Quick filters

Clinical trials for Factor IX deficiency

13 trials across Europe

See all trials →

Quick filters

13 Clinical trials

Factor VIII deficiency+1

Recruiting

InvestigationalNo placebo

A study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B

InvestigationalNo placebo

France

Participants:18–64 years
Substances:Fidanacogene Elaparvovec
Sponsor:Pfizer Inc.

Contact Research Centre

Factor IX deficiency

Recruiting

Registered drugNo placebo

Study of Etranacogene Dezaparvovec (CSL222) in Adolescent Males with Severe or Moderately Severe Hemophilia B

Registered drugNo placebo

Austria

Participants:0–17 years
Substances:Etranacogene Dezaparvovec
Sponsor:CSL Behring LLC

Contact Research Centre

Factor IX deficiency

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Adults with Severe or Moderately Severe Hemophilia B and AAV5 Antibodies

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Etranacogene Dezaparvovec
Sponsor:CSL Behring LLC

Contact Research Centre

Factor IX deficiency

Recruiting

InvestigationalNo placebo

Study on the Safety and Effectiveness of REGV131 and LNP1265 for Adults with Hemophilia B

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Adeno-Associated Virus Vector Serotype 8 Containing The Human F9 Gene
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Factor VIII deficiency+3

Recruiting

InvestigationalNo placebo

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Concizumab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Factor VIII deficiency+1

Recruiting

InvestigationalNo placebo

Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Marstacimab
Sponsor:Pfizer Inc.

Contact Research Centre

See all trials →

Factor IX deficiency

Clinical trials for Factor IX deficiency

Factor VIII deficiency+1

A study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B

Factor IX deficiency

Study of Etranacogene Dezaparvovec (CSL222) in Adolescent Males with Severe or Moderately Severe Hemophilia B

Factor IX deficiency

Study on the Safety and Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Adults with Severe or Moderately Severe Hemophilia B and AAV5 Antibodies

Factor IX deficiency

Study on the Safety and Effectiveness of REGV131 and LNP1265 for Adults with Hemophilia B

Factor VIII deficiency+3

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

Factor VIII deficiency+1

Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.